Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOK | Q9UQ07 | 2/20 | 0.80 |
| ▸ | TACR3 | P29371 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.63 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23722872 | 0.93 | HTT (0.75) | MOKTACR3HTTALDH1A1MEN1 | |
| SCHEMBL23722878 | 0.92 | MOK (0.76) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL19475306 | 0.89 | MOK (1.00) | MOKALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL23722912 | 0.89 | MOK (0.68) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL23722876 | 0.88 | KDM4E (0.72) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL23722836 | 0.88 | MOK (0.64) | MOKTACR3ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23723077 | 0.88 | MOK (0.64) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL24449147 | 0.87 | MOK (0.66) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL23722922 | 0.86 | MOK (0.65) | MOKTACR3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL23746385 | 0.86 | MOK (0.65) | MOKTACR3HTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | AR, KLK3, BRDT | MOK 4545/4885TACR3 447/4885HTT 2642/4885 |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | MOK 4872/4885TACR3 2963/4885HTT 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.